AfroCentric consolidates its pharmaceuticals business
AfroCentric has reached an agreement to fully take over drug importer Activo, positioning itself to compete with pharmaceutical giants
AfroCentric, the owner of Medscheme and Pharmaceutical Direct, is positioning itself to compete with pharmaceutical giants after announcing on Tuesday that it has reached an agreement to acquire a further 74 percent stake in drug importing company Activo. The black-owned investment company, which is partly owned by Sanlam, already owns 26 percent of Activo. Getting full control of the company will make it a significant player in the pharmaceutical industry. "Though Activo competes with significantly bigger companies, like Aspen and Adcock Ingram, the pharmaceutical cluster is becoming an important part of our portfolio. It now contributes about 30 percent of the group's revenue. This is a meaningful transaction. It's a growing asset that is complementary our offering," said AfroCentric CFO Hannes Boonzaaier. The transaction is still subject to regulatory and AfroCentric shareholders' approval, and will be effective from January 1 2019. AfroCentric will pay R588m for the transaction ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.